New Dog Arthritis Therapy Offers Year-Long Relief with Minimal Risk

ATLANTA, GA – January 28, 2026 – For the millions of dog owners who watch their aging companions struggle with the pain of arthritis, a new peer-reviewed study offers significant hope. A groundbreaking radiotherapy treatment, Synovetin OA®, can provide up to a full year of pain relief from a single injection, and new research confirms it does so with an exceptional safety profile, posing minimal radiation risk to pets or their human families.

Osteoarthritis (OA) is a relentless and progressive disease, affecting one in four adult dogs and as many as 80% of seniors. The condition causes chronic pain, lameness, and a diminished quality of life. Now, a comprehensive review published in the Journal of the American Veterinary Medical Association (JAVMA) validates a new approach that targets the disease at its source, potentially transforming long-term care for arthritic dogs.

A New Standard for Safety and Efficacy

The JAVMA publication, titled "Tin-117m radiosynoviorthesis safely and effectively manages canine osteoarthritis with minimal radiation exposure," provides a critical stamp of approval for the treatment. The research consolidates findings from multiple studies, confirming that the radiation exposure to pet owners and veterinary staff is a small fraction of the allowance set by the U.S. Nuclear Regulatory Commission (NRC).

"This research addresses safety and efficacy for treated dogs and confirms that any exposure to owners of dogs treated with Synovetin OA is only a fraction of the allowances set by the federal government," stated Bob Menardi, DVM, Chief Veterinary Officer at Exubrion Therapeutics, the company behind the treatment.

According to published data cited in the press release, the average radiation exposure to family members was just 9.2 millirem (mrem). To put this in perspective, the NRC's annual public allowance is 100 mrem. "For reference, 100 mrem of radiation is roughly equivalent to the amount found in three human abdominal X-rays," Dr. Menardi added. "The average exposure... was about what someone gets from plane travel." This data alleviates a primary concern associated with any radiotherapy, assuring owners that they can safely live with and care for their pets post-treatment.

Beyond its safety, the treatment's effectiveness is a key focus. Clinical trials have demonstrated sustained improvements in mobility and significant reductions in pain scores reported by caregivers, with the benefits of a single injection lasting up to 12 months.

How Targeted Radiotherapy Works

Unlike traditional daily medications that circulate throughout the body, Synovetin OA® works locally. The treatment involves a procedure called radiosynoviorthesis (RSO), which has been used in human medicine for decades. A veterinarian injects microscopic particles of a medical radioisotope, tin-117m (Sn-117m), directly into the arthritic joint.

These particles are absorbed by the inflamed joint lining, or synovium, which is the primary driver of OA pain and progression. The Sn-117m emits low-energy electrons that have a very short range—about 0.3 millimeters—and a half-life of 14 days. This targeted energy reduces the harmful inflammatory cells within the joint, breaking the destructive cycle of inflammation and cartilage breakdown without affecting surrounding healthy tissue or traveling to other parts of the body. Since its introduction in 2021, veterinarians have reported no systemic side effects.

This localized approach is what sets it apart. By addressing the underlying inflammation rather than just masking pain signals, the therapy offers a more fundamental solution. Preclinical research even suggests it has a disease-modifying effect, with the potential to slow the progression of arthritis over time.

Beyond Daily Pills: A Shift in Arthritis Management

The current standard of care for many arthritic dogs involves daily Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). While effective for pain management, these systemic drugs can have side effects on the liver, kidneys, and gastrointestinal tract, often requiring regular bloodwork and monitoring. For owners, this means the daily task of administering pills and the persistent worry of long-term health impacts.

Synovetin OA® presents a paradigm shift. A single, quick outpatient procedure can replace 365 days of pills. This convenience is a significant benefit for both pets and their owners, simplifying care and improving compliance. It is particularly valuable for dogs that cannot tolerate NSAIDs or for whom other treatments have failed.

When compared to other interventions, the treatment also holds a unique position. While newer monthly injections of monoclonal antibodies target pain pathways, Synovetin OA® targets the inflammatory engine of the disease itself. Its annual administration schedule stands in contrast to other joint injections like hyaluronic acid, which may need to be repeated every few months. The long-lasting effect from a single treatment offers a compelling alternative for managing this chronic condition.

The Veterinary Clinic Perspective

Adopting this advanced therapy requires a commitment from veterinary practices. Because Synovetin OA® uses a radioactive material, clinics must obtain a specific Radioactive Materials (RAM) license from the NRC and state regulators. This process involves staff training, designated handling areas, and specialized equipment like Geiger counters and lead-lined containers. While Exubrion Therapeutics provides support to navigate this process, it represents an upfront investment for a clinic.

However, for practices that make the investment, it provides a powerful and unique tool for treating a very common and difficult disease. The upfront cost for a pet owner, which can range from $2,500 to $4,000 for one or two joints, is often comparable to the annual cost of daily high-end NSAIDs, frequent vet visits, and required monitoring, which can easily total $1,500 to $2,000 per year. Furthermore, the treatment is covered by major pet insurance providers, making it an accessible option for many.

For countless dogs suffering from the debilitating effects of arthritis, this innovative, localized therapy represents a renewed chance at a comfortable, active life, and the latest research provides the scientific validation that veterinarians and pet owners have been waiting for.